GeoVax announced promising results in testing a Lassa hemorrhagic fever vaccine (LASV) in mice. Read More »

Final study shows immediate reversal of Pradaxa; anticoagulant drug's effect negated by Praxbind. Read More »

Helps reduce Parkinson's symptoms when primary medications are not completely effective; patients' voluntary movements not impaired by addition of XADAGO. Read More »

Certain workplace necessities just became easier for employees seeking routine screenings and basic health care services thanks to a partnership between CVS MinuteClinic and Alere eScreen Occupational Health Network (EOHN) expanding access via participating locations. Read More »

Two third generation hepatitis B vaccine trials to enroll 4,800 participants in the U.S., Canada and Europe. Read More »

DelMar Pharmaceuticals of Vancouver, British Columbia recently appointed two individuals to its board of directors, in alignment with its mission both to strengthen the board and to allow for expansion of its current executive’s scope. Read More »

Takeda Pharmaceuticals Ltd. and Seattle Genetics Inc. recently announced that their Adcetris drug, which was created to treat advanced Hodgkin lymphoma, met its primary endpoint during the Phase 3 Echelon-1 clinical trial. Read More »

Via tax-free allotment to company shareholders, Rennova Health Inc. intends to transition its Advanced Molecular Services Group to a publicly traded entity by late September pending appropriate paperwork with the SEC and other conditions. Read More »

A bill mandating pharmacy benefit managers obtain a license to conduct business in California and release information to health plans and other purchasers is moving through the state's legislature. Read More »

Specialists at information analytics company Elsevier recently announced that its 2017 season for “The Hive,” its source for rising biotech and pharmaceutical companies, is gearing up with unlimited nomination spots now open for aspiring entrants. Read More »

Sanofi and Regeneron Pharmaceuticals Inc. recently announced positive results for a Phase 1 study evaluating investigational REGN2810, a checkpoint inhibitor targeting PD-1 (programmed death 1) in patients with advanced cutaneous squamous cell carcinoma. Read More »

Suggesting ways to reduce prescription drug costs plus overall marketplace guidance, the Pharmaceutical Care Management Association recently wrote to Health and Human Services Secretary Tom Price, detailing potential pricing and savings allocation improvements. Read More »

West Pharmaceutical Services Inc. presented on best practices for improving patient outcomes through integrated containment and delivery systems at the Sixth Annual InnoPack Pharma Confex in Mumbai, India. Read More »

Amgen's Phase 2 study evaluating Imlygic combined with Yervoy as a treatment for patients with unresectable Stage IIIB-IV met its​ primary endpoint. Read More »

Merck KGaA will collaborate with F-Star, a biopharmaceutical company in the United Kingdom, to develop and commercialize five bispecific immuno-oncology antibodies. Read More »

Amgen's Xgeva Phase 3 study, the largest international multiple myeloma trial ever conducted, met its primary endpoint by demonstrating that the drug is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma. Read More »

AbbVie recently announced positive follow-up results for its pivotal Phase 3 Resonate trial, which evaluated Imbruvica as a treatment for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). Read More »

HedgePath Pharmaceuticals Inc. (HPPI) recently announced that the U.S. Food and Drug Administration (FDA) granted the company’s Type-C Guidance Meeting Request for further guidance on HPPI’s Phase 2(b) clinical trial analyzing SUBA-Itraconazole (SUBA-Cap) oral capsule usage in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome. Read More »

Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for Sutent. Read More »

Novoteris LLC's Phase 2 clinical trial application for inhaled nitric oxide as a treatment for cystic fibrosis has been approved by both the U.S. Food and Drug Administration and the Therapeutic Products Directorate of Health Canada. Read More »